Whitepaper

ASCO Reveals: Increasing Options for Relapse/ Refractory Patients in Haematological Malignancies
Hope for patients living with haematological malignancies; Immunotherapies represent a novel class of biologics
ASCO Reveals: Increasing Options for Relapse/ Refractory Patients in Haematological Malignancies

More Whitepapers / Newsletters

Hereditary ATTR (hATTR) Amyloidosis Newsletter
Hereditary ATTR (hATTR) Amyloidosis

Transthyretin Amyloidosis (ATTR) is a progressive build-up of abnormal deposits of amyloid protein in the body's organs...

Cancer Globally (Vol. 1, Issue 1) Newsletter
Cancer Globally (Vol. 1, Issue 1)

Cancer has gripped the human society in its clutches in such a way that there has been many advancements to treat the same, but with little...

Current Treatment Challenges of IO Refractory Patients and Clinical Development of Therapies Targeting These Patients Whitepaper
Current Treatment Challenges of IO Refractory Patients and Clinical Development of Therapies Targeting These Patients

Over the years, the Oncology domain has experienced the entry of several treatment approaches. Therapeutic approaches such as surgery, radiation therapy...

Cutaneous Lupus Erythematosus Newsletter
Cutaneous Lupus Erythematosus

An autoimmune disease in which the immune system attacks its healthy skin, Cutaneous Lupus Erythematosus, belongs to the family of..

Raynauds phenomenon Newsletter
Raynaud's phenomenon

Raynaud’s phenomenon (RP) is a condition that results in discoloration of fingers or toes caused by episodic vasospasm...